Amiodarone induced thyrotoxicosis: Diagnostic and therapeutic strategies

Gustavo A. Cardenas, MD
Section of Preventive Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic

José M. Cabral, MD
Department of Endocrinology, Cleveland Clinic Florida

Camilo A. Leslie, MD, MBA
Department of Endocrinology, Cleveland Clinic Florida; Associate Professor of Medicine (affiliate), University of South Florida College of Medicine

Address: Camilo A. Leslie, MD, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Florida Boulevard, Weston, FL 33331; email: lesliec2@ccf.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gustavo A. Cardenas, MD
Section of Preventive Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic

José M. Cabral, MD
Department of Endocrinology, Cleveland Clinic Florida

Camilo A. Leslie, MD, MBA
Department of Endocrinology, Cleveland Clinic Florida; Associate Professor of Medicine (affiliate), University of South Florida College of Medicine

Address: Camilo A. Leslie, MD, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Florida Boulevard, Weston, FL 33331; email: lesliec2@ccf.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gustavo A. Cardenas, MD
Section of Preventive Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic

José M. Cabral, MD
Department of Endocrinology, Cleveland Clinic Florida

Camilo A. Leslie, MD, MBA
Department of Endocrinology, Cleveland Clinic Florida; Associate Professor of Medicine (affiliate), University of South Florida College of Medicine

Address: Camilo A. Leslie, MD, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Florida Boulevard, Weston, FL 33331; email: lesliec2@ccf.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.